SCHEMBL18765734

SCHEMBL18765734

O=C(O)N1Cc2cc(F)ccc2CC1CO

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ DPP9 Q86TI2 10/20 0.40
▸ MAPK1 P28482 1/20 0.39
▸ DPP8 Q6V1X1 7/20 0.39
▸ DPP4 P27487 6/20 0.39
▸ DPP7 Q9UHL4 5/20 0.38
▸ NR1D1 P20393 1/20 0.38
▸ AKR1C3 P42330 1/20 0.37
▸ OPRD1 P41143 2/20 0.36
▸ OPRM1 P35372 1/20 0.36
▸ OPRK1 P41145 1/20 0.36
▸ HTR1A P08908 1/20 0.36
▸ DRD2 P14416 1/20 0.36
▸ HTR2A P28223 1/20 0.36
▸ SLC6A4 P31645 1/20 0.36
▸ HTR7 P34969 1/20 0.36
▸ DRD3 P35462 1/20 0.36
▸ HTR2B P41595 1/20 0.36
▸ BCL2 P10415 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18765733 1.00 DPP9 (0.40) DPP9MAPK1DPP8DPP4DPP7
SCHEMBL2731004 0.84 BCL2 (0.41) AKR1C3DRD2HTR2AHTR2BBCL2
SCHEMBL29676732 0.82 HDAC8 (0.48) DPP9DPP8DPP4DPP7NR1D1
SCHEMBL20720097 0.82 HDAC8 (0.48) DPP9DPP8DPP4DPP7NR1D1
SCHEMBL18793351 0.82 HDAC8 (0.48) DPP9DPP8DPP4DPP7NR1D1
SCHEMBL4595358 0.80 BCL2 (0.47) NR1D1BCL2
SCHEMBL17559495 0.80 BCL2 (0.47) NR1D1BCL2
SCHEMBL17559498 0.80 BCL2 (0.47) NR1D1BCL2
SCHEMBL25242304 0.80 HTR1A (0.39) DPP9DPP8DPP4DPP7NR1D1
SCHEMBL20720152 0.79 OPRD1 (0.47) DPP9DPP8DPP4DPP7OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11939321-B2 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-03-26 — — US disclosed
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-01-19 — — US disclosed
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-05-11 — — US disclosed
US-10457669-B2 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-10-29 — — US disclosed
US-20190047990-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-02-14 — — US disclosed
EP-3365334-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS Otsuka Pharmaceutical Co., Ltd. (JP) 2018-08-29 — — EP disclosed
WO-2017068412-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2017-04-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11939321-B2 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 DPP9 4594/4885MAPK1 1/4885DPP8 4849/4885
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 DPP9 4594/4885MAPK1 1/4885DPP8 4849/4885
US-20190047990-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 DPP9 4594/4885MAPK1 1/4885DPP8 4849/4885
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 DPP9 4611/4885MAPK1 1/4885DPP8 4853/4885
US-10457669-B2 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 DPP9 4594/4885MAPK1 1/4885DPP8 4849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback